The **GSK stock** has seen a surge in its **trading volume**, ranking it 229th in the global market. In recent months, the stock has risen almost 22%, prompting investors to question whether now is the time to buy. However, it experienced a setback when its blood cancer drug, **Blenrep**, was likely to face rejection in the U.S. Meanwhile, it won EU approval for the same drug. Following this, GSK shares ended the week strong, supported by the EU approval of **Blenrep**. Unfortunately, a subsequent FDA committee vote left GSK's cancer-drug comeback in doubt. More importantly, GSK has been expanding its treasury holdings with its latest **share buyback** and is cautioning investors ahead of its earnings release. With the stock down 18% since September, many are considering capitalizing on GSK’s lower share price. Conversely, other investors maintain a **sell rating** on GSK, blaming fears over regulatory rejection risks and the long-term resilience of the company's R&D efforts.
GSK Stocks News Analytics from Wed, 05 Feb 2025 08:00:00 GMT to Fri, 25 Jul 2025 19:00:53 GMT -
Rating 2
- Innovation 7
- Information 4
- Rumor -6
